Provention Bio, Inc. PRVB
At closeApr 26, 2023, 4:00 PM EDT
- Market cap
- 2.38B
- Revenue (ttm)
- 12.89M
- EPS (ttm)
- -1.52
- Shares out
- 91.10M
- P/E ratio
- -16.43
- Forward P/E
- -192.15
- Volume
- 9.12M
- Avg volume
- 2.84M
- Open
- 24.99
- Previous close
- 24.98
- Day's range
- 24.98 – 25.00
- 52-week range
- 3.19 – 25.00
- Beta
- 2.46
- Analysts
- Buy
- Price target
- 23.50 (-5.9%)
- Earnings date
- May 4, 2023
2Y +18.14 (+265.20%)
Key statistics
- Enterprise value
- 2.17B
- PEG ratio
- 0.00
- Price / sales
- 184.21
- Price / book
- 17.97
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 1408.10%
- Free cash flow
- 2.87M
- Total cash
- 165.00M
- Total debt
- 24.06M
- Return on equity
- -97.66%
- Short % of float
- 7.58%
- 50-day average
- 19.10
- 200-day average
- 10.15
Analyst view
Consensus: buy
- Target (low)
- 19.00
- Target (mean)
- 23.50
- Target (high)
- 25.00
- Strong buy1
- Buy2
- Hold3
- Sell0
- Strong sell0
Next earnings
May 4, 2023
Expected May 4, 2023. Consensus EPS estimate -1.54.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 4, 2023 | Mar 1, 2023 | -0.97 | — | — | — |
| Nov 3, 2022 | Sep 1, 2022 | -0.46 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -0.49 | — | — | — |
| May 5, 2022 | Mar 1, 2022 | -0.45 | — | — | — |
| Feb 24, 2022 | Dec 1, 2021 | -0.44 | — | — | — |
| Nov 4, 2021 | Sep 1, 2021 | -0.47 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 15, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Mar 14, 2023 | SMBC Nikko | down | Outperform | Neutral |
| Mar 14, 2023 | Jefferies | down | Buy | Hold |
| Mar 13, 2023 | Chardan Capital | main | — | Buy |
| Feb 15, 2023 | HC Wainwright & Co. | main | — | Buy |
| Nov 21, 2022 | SVB Leerink | main | — | Outperform |
About Provention Bio, Inc.
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- proventionbio.com
News
Earnings Scheduled For March 16, 2023 
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023 - Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Illumina, Seagen And Other Big Stocks Moving Higher On Monday 
Stocks That Hit 52-Week Lows On Friday 
Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday - Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday
- Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session
Earnings Scheduled For November 3, 2022 
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
Your note
Sign in to keep a note on PRVB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BLUESTONE JEFFREY PH.D. | Director | Conversion of Exercise of derivative security | Apr 9, 2020 | 0 |
| CATLIN AVERY W | Director | Stock Gift | Apr 12, 2023 | 20,000 |
| DIGIANDOMENICO ANTHONY | Director | Purchase | Sep 29, 2019 | 178,712 |
| DRECHSLER ANDREW T | Chief Financial Officer | Purchase | Sep 1, 2020 | 20,000 |
| HOITT JASON | Officer | Sale | Feb 9, 2023 | 0 |
| LEON FRANCISCO | Officer | Stock Gift | Apr 12, 2023 | 146,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sessa Capital IM, L.P. | 15.70% | 14,879,023 | 371.68M | Dec 30, 2022 |
| Blackrock Inc. | 5.89% | 5,579,604 | 139.38M | Dec 30, 2022 |
| Vanguard Group, Inc. (The) | 4.37% | 4,142,744 | 103.49M | Dec 30, 2022 |
| Adage Capital Partners GP L.L.C. | 2.66% | 2,519,257 | 62.93M | Dec 30, 2022 |
| State Street Corporation | 1.64% | 1,558,238 | 38.92M | Dec 30, 2022 |
| Geode Capital Management, LLC | 1.39% | 1,322,189 | 33.03M | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.69% | 2,553,871 | 63.80M | Dec 30, 2022 |
| iShares Russell 2000 ETF | 1.46% | 1,380,809 | 34.49M | Feb 27, 2023 |
| Vanguard Extended Market Index Fund | 1.11% | 1,052,768 | 26.30M | Dec 30, 2022 |
| iShares NASDAQ Biotechnology ETF | 0.67% | 635,394 | 15.87M | Feb 27, 2023 |
| Fidelity Small Cap Index Fund | 0.55% | 521,048 | 13.02M | Jan 30, 2023 |
| Principal Capital Appreciation Fund | 0.49% | 460,658 | 11.51M | Jan 30, 2023 |